在多发性骨髓瘤治疗中准卡韦奥林-1的分子基础
Dewen Zhan1,2, Kim De Veirman2,3, Yuhe Guan1,4
1The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University Guangzhou, China.
Expert opinion on therapeutic targets
|January 26, 2026
概括
向Caveolin-1 (Cav-1) 提供了一种针对多发性骨髓瘤 (MM) 复发和治疗耐药性的新策略. 阻断Cav-1可以增强药物敏感性,改善MM患者的免疫反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 多发性骨髓瘤 (MM) 是一种血细胞癌,以频繁复发和耐治疗性而闻名.
- 卡维奥林-1 (Cav-1) 是一种形成等离子体膜洞穴的蛋白质,它影响细胞信号传递,新陈代谢,自和骨髓微环境相互作用.
研究的目的:
- 审查Cav-1在MM进展和治疗耐药性的作用.
- 总结针对Cav-1的临床前策略,并讨论临床翻译的挑战.
主要方法:
- 在多发性骨髓瘤中对Cav-1的研究的文献综述.
- 分析临床前方法,包括小分子,,基于RNA的方法和CRISPR.
- 讨论组合疗法和临床翻译中的挑战.
主要成果:
- 在骨髓微环境中,Cav-1在MM细胞存活,粘附和通信方面发挥着重要作用.
- 临床前的策略显示了向Cav-1的潜力,包括与蛋白酶体抑制剂结合使用.
- 挑战包括需要选择性抑制剂和管理潜在的毒性.
结论:
- 在MM中,Cav-1代表着一种上下文依赖的治疗脆弱性.
- 向Cav-1可以恢复药物敏感性,减少骨髓微环境的保护作用,增强抗瘤免疫力.
- 开发对Cav-1抑制剂的选择性或瘤向的输送机制对于在耐药MM中有效的组合治疗至关重要.
相关概念视频
Targeted Cancer Therapies
8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.7K
Multiple Allele Traits
38.0K
The Concept of Multiple Allelism
38.0K
Molecular Orbital Theory II
27.1K
Molecular Orbital Energy Diagrams
27.1K
Molecular Orbital Theory I
47.2K
Overview of Molecular Orbital Theory
47.2K
Molecular Models
43.6K
Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
43.6K
Gene Therapy
27.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K


